Pipeline
Denifanstat Pipeline on Multiple Indications and Clinical Milestones

Therapeutic area
Indication
Preclinical
Phase 1
Phase 2
Phase 3
* Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China